Natalizumab Completed Phase 2 Trials for Multiple Sclerosis, Primary Progressive / Secondary Progressive Multiple Sclerosis (SPMS) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01077466Natalizumab Treatment of Progressive Multiple Sclerosis